FORA Capital’s Novavax NVAX Stock Holding History

FORA Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,556	Closed	-$385K	–	1071
2020 Q3	$385K	Buy	+3,556	New	+$433K	0.25%	86

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FORA Capital's NVAX Position: Q4 2020 in Review

FORA Capital sold out of Novavax (NVAX) in Q4 2020, closing a stake of 3,556 shares — an estimated $385K sold.

FORA Capital first reported a position in NVAX in Q3 2020 and held it in 1 quarter. The position peaked at $385K in Q3 2020. 347 funds tracked by Wall St. Rank hold NVAX as of Q4 2020.

FORA Capital reported no remaining Novavax position as of Q4 2020 after selling out during the quarter.
FORA Capital sold 3,556 Novavax shares in Q4 2020, an estimated $385K.
FORA Capital first reported a position in Novavax in Q3 2020 and held it in 1 quarter.
FORA Capital's Novavax position peaked at $385K in Q3 2020.
347 funds tracked by Wall St. Rank held Novavax as of Q4 2020.

Based on FORA Capital's 13F filing for Q4 2020, filed 12 Feb 2021.